Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Buy” by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has received an average rating of “Buy” from the nine research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and three have given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $11.3333.

Several research firms have recently weighed in on ACRS. Canaccord Genuity Group started coverage on shares of Aclaris Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $10.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Wednesday, June 24th. Lifesci Capital initiated coverage on shares of Aclaris Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $13.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Aclaris Therapeutics Stock Up 3.7%

NASDAQ:ACRS opened at $6.17 on Friday. Aclaris Therapeutics has a 1-year low of $1.74 and a 1-year high of $6.60. The firm has a market capitalization of $862.71 million, a price-to-earnings ratio of -10.64 and a beta of 0.79. The stock has a fifty day simple moving average of $5.77 and a 200 day simple moving average of $4.67.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.The firm had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.38 million. Equities analysts predict that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in Aclaris Therapeutics during the second quarter valued at $34,000. California State Teachers Retirement System boosted its position in Aclaris Therapeutics by 36.9% during the 2nd quarter. California State Teachers Retirement System now owns 6,798 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 1,833 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth about $48,000. BNP Paribas Financial Markets grew its stake in Aclaris Therapeutics by 59.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 9,894 shares in the last quarter. Finally, CIBC Asset Management Inc purchased a new position in Aclaris Therapeutics during the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.